KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

Brett King, Amy McMichael, Rodney Sinclair, Sergio Vañó-Galvan, Robert Wolk, Deborah Woodworth, Koshika Soma, Feriel Robbana, Alexandre Lejeune, Lynne Napatalung, Ernest Law, Dalia Wajsbrot, Cunshan Wang, Satrajit Roychoudhury

Dermatol Ther (Heidelb) 15(12) 3793-3803

PMID41083802
PMCIDPMC12619875
DOI10.1007/s13555-025-01543-7
发表日期2025-10-14
摘要

摘要

INTRODUCTION: Despite recent advancements in treating severe alopecia areata (AA), many patients do not achieve target efficacy with approved therapies. Ritlecitinib is an oral Janus kinase 3 (JAK3)/tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor approved to treat severe AA at a dose of 50-mg once daily (QD). A new phase 3 clinical trial (NCT06873945) described herein evaluates a higher dose of ritlecitinib (100-mg QD) in patients with AA. The study employs an innovative design using patient-level data from patients with similar baseline characteristics from previous AA ritlecitinib studies to form an external placebo control group, a synthetic placebo control group (extrapolating for outcomes over a longer timeframe than captured previously), and an external ritlecitinib 50-mg nonresponders group, eliminating the need to randomize patients to placebo. METHODS: This randomized, double-blind clinical trial investigates the efficacy and safety of ritlecitinib in patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss. Patients are randomized to ritlecitinib 100-mg or 50-mg QD. Those randomized to ritlecitinib 100-mg continue the 100-mg dose through week 48. Patients randomized to ritlecitinib 50-mg with a Severity of Alopecia Tool (SALT) score ≤ 20 at week 24 (responders) continue ritlecitinib 50-mg through week 48; nonresponders at week 24 are rerandomized 2:1 to increase to ritlecitinib 100-mg or continue ritlecitinib 50-mg through week 48. PLANNED OUTCOMES: The primary end point is a SALT score ≤ 20 at week 24 for ritlecitinib 100-mg versus external placebo. Key secondary end points include SALT score ≤ 20 at week 24 for ritlecitinib 50-mg versus external placebo and week 36 for ritlecitinib 100-mg versus synthetic placebo, and SALT score change from baseline at week 24 for ritlecitinib 100-mg versus 50-mg. An external ritlecitinib 50-mg nonresponders control group augments the ritlecitinib 50-mg nonresponders at week 24 rerandomized to ritlecitinib 50-mg to support comparative analyses at week 48. GOV REGISTRATION: NCT06873945. Video Abstract (MP4 303790 kb).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。